References
- Bajetta E, Di Bartolomeo M, Mariani L, et al (2004). Italian Trials in Medical Oncology (I.T.M.O.) Group. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer, 100, 279-87. https://doi.org/10.1002/cncr.11910
- Borner MM, Bernhard J, Dietrich D, et al (2005). Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol, 16, 282-8. https://doi.org/10.1093/annonc/mdi047
- Cartwright T, Lopez T, Vukelja SJ, et al (2005). Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer, 5, 50-6. https://doi.org/10.3816/CCC.2005.n.016
- de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47.
- Douillard JY, Cunningham D, Roth AD, et al (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355,1041-7. https://doi.org/10.1016/S0140-6736(00)02034-1
- Ducreux M, Adenis A, Pignon JP, et al (2013). Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Eur J Cancer, [Epub ahead of print].
- Feliu J, Salut A, Safont M, et al, ONCOPAZ group, (2008). First-line treatment with bevacizumab plus capecitabine for elderly patients with metastatic colorectal cancer: BECA trial. J Clin Oncol, 26, 15120.
- Fernando N, Yu D, Morse M, et al (2005). A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. J Clin Oncol, 23, 3556.
- Fuchs CS, Marshall J, Mitchell E, et al (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol, 25, 4779-86. https://doi.org/10.1200/JCO.2007.11.3357
- Hochster HS, Hart LL, Ramanathan RK, et al (2006). Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREEStudy. J Clin Oncol, 24, 3510. https://doi.org/10.1200/JCO.2006.06.7199
- Koopman M, Antonini NF, Douma J, et al (2007). Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet, 370, 135-42. https://doi.org/10.1016/S0140-6736(07)61086-1
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Ocvirk J, Rebersek M, Boc M (2011). Bevacizumab in firstline therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI. Anticancer Res, 31, 1777-82.
- Pectasides D, Papaxoinis G, Kalogeras KT, et al (2012). XELIRIbevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer,12, 271. https://doi.org/10.1186/1471-2407-12-271
- Rea DW, Nortier JW, Ten Bokkel Huinink WW, et al (2005). A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol, 16, 1123-32. https://doi.org/10.1093/annonc/mdi227
- Reinacher-Schick AC, Kubicka S, Freier W, et al (2008). Activity of the combination of bevacizumab (Bev) with capecitabine/ irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/ Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol, 26, 4030.
- Renouf DJ, Welch S, Moore MJ, et al (2012). A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. Cancer Chemother Pharmacol, 69, 1339-44. https://doi.org/10.1007/s00280-012-1843-9
- Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001). Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol, 19, 3801-7.
- Saltz LB, Cox JV, Blanke C, et al (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 343, 905-14. https://doi.org/10.1056/NEJM200009283431302
- Sobrero AF, Ackland S, Carrion RP, et al (2006). Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol, 24, 3544.
- Souglakos J, Ziras N, Kakolyris S, et al (2012). Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). Br J Cancer, 106, 453-9. https://doi.org/10.1038/bjc.2011.594
- Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, et al (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol, 28, 3191-8. https://doi.org/10.1200/JCO.2009.27.7723
- Tewes M, Schleucher N, Achterrath W, Wilke HJ, Frings S, Seeber Set al (2003). Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Ann Oncol, 14, 1442-8. https://doi.org/10.1093/annonc/mdg376
Cited by
- Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab? vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4781
- Clinical Observations on Associations Between the UGT1A1 Genotype and Severe Toxicity of Irinotecan vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3335
- Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3951
- XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10375
- Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI) vol.36, pp.5, 2015, https://doi.org/10.1007/s13277-014-2970-1